Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and haemodynamic monitoring, announced the results of a pivotal clinical study of high-risk surgical patients with severe aortic stenosis treated in Cohort A of The PARTNER Trial. These data demonstrate that the study achieved its primary endpoint at one year, concluding that survival of patients treated with the Edwards SAPIEN transcatheter aortic valve was equivalent to those treated with surgical aortic valve replacement. The data were presented at the American College of Cardiology’s (ACC) 60th Annual Scientific Session & Expo in New Orleans, LA, USA.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/48895/
A small town lawyer is forced to fight a giant pharmaceutical company and the FDA to try to save his daughter’s life in Thompson’s edgy legal thriller. When his lawsuit uncovers fraud and corruption, he is confronted with an enemy who will resort to bribery, kidnapping and murder to win. Learn about the book and this author, www.larrydthompson.com Mystery Thriller
Performing delicate surgery in the womb, months before birth, can substantially improve outcomes for children with a common, disabling birth defect of the spine. Experts at The Children’s Hospital of Philadelphia (CHOP) co-led a new landmark study showing that fetal surgery for spina bifida greatly reduces the need to divert fluid from the brain, improves mobility and improves the chances that a child will be able to walk independently.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/chop/48124/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company’s novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled,
Back by popular demand, the Recreational Boating & Fishing Foundation’s (RBFF) Take Me Fishing™ campaign is kicking off Catch A Boat 3.0, an online fishing tournament that includes a sweepstakes to win daily prizes or the grand prize boat, motor and trailer. Beginning November 29, 2010 at noon ET, boaters and anglers are invited to take part in TakeMeFishing.org’s interactive game for a chance to reel in the grand prize Stratos fishing boat, provided by the North American Fishing Club (NAFC). NAFC is also offering players a 30-day free trial membership, which includes a free issue of North American Fisherman.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/catchaboat/47487/
Vampires, werewolves, shapeshifters. All the dark creatures that humans want to believe are only myth.They live in the night. And when blood is spilled, justice must be served. Learn more about this book here: http://bit.ly/cT1dti and its author here: www.TheShadowKeepers.com Paranormal Romance
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, reported that The New England Journal of Medicine today published results from Cohort B of The PARTNER Trial, which studied the Edwards SAPIEN transcatheter heart valve for the treatment of severe aortic stenosis. The results of the trial successfully met the primary endpoints of all-cause mortality and mortality plus repeat hospitalization.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/44227/
The largest-ever morbi-mortality study of treatments for chronic heart failure has shown that adding the specific heart rate lowering agent Procoralan® (ivabradine) to standard therapy significantly reduces the risk of death and hospitalisation for heart failure.1 Results from this new study, SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial), were presented today at the European Society of Cardiology1 in Stockholm and published in The Lancet.2
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/shift/44195/
http://www.mb01.com/lnk.asp?o=1951&c=918271&a=56556
The $1000 Totally free Best Buy Present Card Giveaway is definitely an exclusive provide only discovered online. If you are familiar with best buy, maintain reading this write-up to learn how you can get a gift card and go on a purchasing spree completely free.
How it functions
Like numerous other individuals, when I very first heard of obtaining $1000 to go to Greatest Buy and shop for totally free, it believed it was ridiculous. Why would they give out totally free Greatest Purchase cards? Out of curiosity I had to apply for one myself. After completing the surveys I was instructed to apply for any free trial of what ever item interest me and within 1 week I received my $1000 Best Purchase card.
Market research companies give out free gift card and merchandise for exchange of info only buyers can provide. Filling out simple surveys gives valuable info to businesses on how they can enhance their products and how the public benefits to every merchandise. Its less costly to provide out free gifts on the internet than having to pay a huge selection of thousands of dollars on Tv ads. You can also try numerous products for free prior to buying.
As soon as the questionnaire is carried out, you might be asked to sign up for any product or support that offers you a trial offer. This is a win/win scenario. You do not need to purchase the item, just make sure you choose out a offer that curiosity you. This really is crucial for that Free Best Purchase Present Card Giveaway promotion. Many people only do the survey and forget concerning the free trial provide and never receive their card.
In reality the Free Best Purchase Gift Card Giveaway is not really totally free. You
C. R. Bard, Inc. today announced the publication of RESILIENT trial results by Circulation: Cardiovascular Interventions showing the Bard LifeStent® Vascular Stent improved patency and reduced revascularization rates in patients with moderate-length lesions in the superficial femoral artery (SFA) and proximal popliteal artery compared to patients treated with percutaneous transluminal angioplasty (PTA).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bard/44623/
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pvct/43978/
